Cargando…

Up-regulation of miR-370-3p restores glioblastoma multiforme sensitivity to temozolomide by influencing MGMT expression

MicroRNAs (miRNA) are believed to play an important role in glioblastoma multiforme (GBM)chemotherapy. Our study aims to investigate potential miRNA biomarkers in GBM. Sixty GBM patients, which were given temozolomide (TMZ) chemotherapy and recurrent radiotherapy, were recruited. miRNA array was per...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Yong-tao, Chen, Xiao-bing, Liu, Hong-lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5011744/ https://www.ncbi.nlm.nih.gov/pubmed/27595933 http://dx.doi.org/10.1038/srep32972

Ejemplares similares

Overexpression miR-486-3p Promoted by Allicin Enhances Temozolomide Sensitivity in Glioblastoma Via Targeting MGMT
por: Wu, Henggang, et al.
Publicado: (2020)

miR-370 Sensitizes TMZ Response Dependent of MGMT Status in Primary Central Nervous System Lymphoma
por: Li, Xinwei, et al.
Publicado: (2019)

Exosomal circWDR62 promotes temozolomide resistance and malignant progression through regulation of the miR-370-3p/MGMT axis in glioma
por: Geng, Xiuchao, et al.
Publicado: (2022)

Role of miR-223/paired box 6 signaling in temozolomide chemoresistance in glioblastoma multiforme cells
por: Cheng, Quan, et al.
Publicado: (2017)

The Role of miRNA for the Treatment of MGMT Unmethylated Glioblastoma Multiforme
por: Kirstein, Anna, et al.
Publicado: (2020)

Identification of MGMT Downregulation Induced by miRNA in Glioblastoma and Possible Effect on Temozolomide Sensitivity
por: Cardia, Andrea, et al.
Publicado: (2023)

Temozolomide resistance in glioblastoma multiforme
por: Lee, Sang Y.
Publicado: (2016)

miR-340 suppresses glioblastoma multiforme
por: Huang, Daquan, et al.
Publicado: (2015)

Advances in the management of glioblastoma: the role of temozolomide and MGMT testing
por: Thomas, Reena P, et al.
Publicado: (2012)

Suppressing TRAP1 sensitizes glioblastoma multiforme cells to temozolomide
por: Wang, Nan, et al.
Publicado: (2021)

Interfering with mitochondrial dynamics sensitizes glioblastoma multiforme to temozolomide chemotherapy
por: Wang, Nan, et al.
Publicado: (2021)

BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression
por: Tancredi, Alessandro, et al.
Publicado: (2022)

Downregulation of MGMT expression by targeted editing of DNA methylation enhances temozolomide sensitivity in glioblastoma
por: Han, Xinyu, et al.
Publicado: (2023)

Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide
por: van Nifterik, K A, et al.
Publicado: (2010)

miR-370 mimic inhibits replication of Japanese encephalitis virus in glioblastoma cells
por: Li, Wenjuan, et al.
Publicado: (2016)

Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status
por: Wu, Qiong, et al.
Publicado: (2023)

MiR-181 Family Modulates Osteopontin in Glioblastoma Multiforme
por: Marisetty, Anantha, et al.
Publicado: (2020)

miR-130a can predict response to temozolomide in patients with glioblastoma multiforme, independently of O6-methylguanine-DNA methyltransferase
por: Chen, Huiyuan, et al.
Publicado: (2015)

Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival
por: Rahman, Mohummad Aminur, et al.
Publicado: (2019)

Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma
por: Yin, Jianxing, et al.
Publicado: (2019)

Lomeguatrib Increases the Radiosensitivity of MGMT Unmethylated Human Glioblastoma Multiforme Cell Lines
por: Kirstein, Anna, et al.
Publicado: (2021)

Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy
por: Dunn, J, et al.
Publicado: (2009)

A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
por: Chen, Xiaoyue, et al.
Publicado: (2018)

The Impact of MGMT Promoter Methylation and Temozolomide Treatment in Serbian Patients with Primary Glioblastoma
por: Jovanović, Nikola, et al.
Publicado: (2019)

Phase II trial of concurrent sunitinib, temozolomide, and radiotherapy with adjuvant temozolomide for newly diagnosed MGMT unmethylated glioblastoma
por: Faye, Mame Daro, et al.
Publicado: (2023)

EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma
por: Struve, Nina, et al.
Publicado: (2020)

A genome-wide miRNA screen revealed miR-603 as a MGMT-regulating miRNA in glioblastomas
por: Kushwaha, Deepa, et al.
Publicado: (2014)

The role of miR-370 in fibrosis after myocardial infarction
por: Yuan, Hui, et al.
Publicado: (2017)

MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression
por: Chen, Wei, et al.
Publicado: (2017)

Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice
por: van Genugten, J. A. B., et al.
Publicado: (2009)

Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems
por: Toren, Amos, et al.
Publicado: (2016)

The Potential of miR-370-3p and miR-495-3p Serving as Biomarkers for Sepsis-Associated Acute Kidney Injury
por: Ma, Wenlu, et al.
Publicado: (2022)

MGMT and Whole-Genome DNA Methylation Impacts on Diagnosis, Prognosis and Therapy of Glioblastoma Multiforme
por: Della Monica, Rosa, et al.
Publicado: (2022)

Tumor suppressive role of miR-194-5p in glioblastoma multiforme
por: Zhang, Zhao, et al.
Publicado: (2017)

Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital
por: Egaña, Larraitz, et al.
Publicado: (2020)

On the Critical Issues in Temozolomide Research in Glioblastoma: Clinically Relevant Concentrations and MGMT-independent Resistance
por: Stepanenko, Aleksei A., et al.
Publicado: (2019)

Lack of Benefit of Extending Temozolomide Treatment in Patients with High Vascular Glioblastoma with Methylated MGMT
por: Álvarez-Torres, María del Mar, et al.
Publicado: (2021)

Elimination of Cancer Stem-Like Cells and Potentiation of Temozolomide Sensitivity by Honokiol in Glioblastoma Multiforme Cells
por: Lai, I-Chun, et al.
Publicado: (2015)

MiR-21, miR-34a, miR-125b, miR-181d and miR-648 levels inversely correlate with MGMT and TP53 expression in primary glioblastoma patients
por: Jesionek-Kupnicka, Dorota, et al.
Publicado: (2017)

Up-Regulation of Hsa-miR-11181 in Glioblastoma Multiforme as A Regulator of AKT and TGFBR1 Signalling
por: Dabiri, Hamed, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_slim14qq405s0dnihavvuc7gdb